146 related articles for article (PubMed ID: 23394351)
1. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.
Sucak GT; Çakar MK; Suyanı E; Akı Z; Altındal Ş; Acar K
Hematology; 2013 Sep; 18(5):269-76. PubMed ID: 23394351
[TBL] [Abstract][Full Text] [Related]
2. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[TBL] [Abstract][Full Text] [Related]
3. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
5. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
7. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
10. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
12. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I
Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Sperotto A; Damiani D; Zaja F; Patriarca F; Geromin A; Cerno M; Stocchi R; Tiribelli M; Skert C; Rinaldi C; Fanin R
Adv Clin Path; 2002 Apr; 6(2):77-85. PubMed ID: 19753729
[TBL] [Abstract][Full Text] [Related]
16. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
Martínez C; Salamero O; Arenillas L; Duque J; López-Guillermo A; Rovira M; Urbano-Ispízua A; Fernández-Avilés F; Carreras E; Montserrat E
Leuk Lymphoma; 2007 Oct; 48(10):1968-75. PubMed ID: 17917965
[TBL] [Abstract][Full Text] [Related]
18. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.
Fung HC; Stiff P; Schriber J; Toor A; Smith E; Rodriguez T; Krishnan A; Molina A; Smith D; Ivers B; Kogut N; Popplewell L; Rodriguez R; Somlo G; Forman SJ; Nademanee A
Biol Blood Marrow Transplant; 2007 May; 13(5):594-600. PubMed ID: 17448919
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
[TBL] [Abstract][Full Text] [Related]
20. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz JP; Munck JN; Divine M; Fermé C; Pény AM; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau JL
Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
